2025-12-19 - Analysis Report
Okay, here's a comprehensive analysis of UnitedHealth Group (UNH) based on the data provided.

**0. Report Creation Conventions:**

*   All values are based on the provided data as of the available date (most likely late December 2025).
*   "Current" refers to the most recent data point available.

**1. Return Rate Comparison: UNH vs. S&P 500 (VOO)**

*   **Ticker:** UNH (UnitedHealth Group Inc.)
*   **Company Overview:** UnitedHealth Group is a diversified health care company providing a wide range of health benefits and services.
*   **UNH Cumulative Return:** -18.22%
*   **VOO Cumulative Return:** 99.09%
*   **Divergence:** -116.5 (Range: -130.7 to 36.3, Relative Divergence: 8.5)

**Analysis:**

*   UNH has significantly underperformed the S&P 500 (VOO) in the period covered by the cumulative return data.
*   The divergence of -116.5 indicates a substantial difference in returns, with VOO performing far better.
*   The relative divergence of 8.5 suggests that this level of underperformance is near the *bottom* of its historical range versus the S&P 500.
* The Alpha and Beta analysis reveals varying performance over different periods. The CAGR fluctuated, and MDD remained consistently high, reflecting significant volatility. The negative Alpha in recent years suggests underperformance relative to the market, while Beta values indicate fluctuating sensitivity to market movements. The Cap(B) values reflect the company's market capitalization.

**2. Recent Stock Price Fluctuations:**

*   **Current Close:** 328.14
*   **Previous Close:** 331.63
*   **Change:** -1.05
*   **5-day SMA:** 335.38
*   **20-day SMA:** 329.19
*   **60-day SMA:** 340.41

**Analysis:**

*   The stock price is currently below all three moving averages, suggesting a short-term downtrend.
*   The 5-day SMA is above the 20-day SMA, but both are below the 60-day SMA, which indicates a potential shift in momentum but overall weakness.
*   The negative change from the previous close further confirms the recent downward trend.

**3. Index Indicators:**

*   **Market Risk Indicator (MRI):** 0.7 (Medium Investment)
*   **RSI:** 48.81 (Neutral)
*   **PPO:** 0.2572
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (2 shares - Safe - MRI:0.80) Dividend_2.21 (Cash Ratio: 0% on 2025-12-08)
*   **Recent (20 days) relative divergence change:** 2.3 (+) - Short-term increase
*   **Expected Return (%):** -216.9%

**Analysis:**

*   The MRI of 0.7 suggests a medium level of investment risk.
*   The RSI of 48.81 is neutral, indicating neither overbought nor oversold conditions.
*   The positive PPO value shows the short-term moving average is trending higher than the long-term moving average.
*   The hybrid signal suggests allocating a majority of cash to UNH, considering it safe, and a dividend of 2.21 is provided, with 0% cash ratio.
*   The positive change in relative divergence over the past 20 days indicates a recent upward trend compared to the S&P 500, although this is occurring against a backdrop of significant underperformance.
*   The dramatically negative Expected Return (%) of -216.9% is extremely concerning and suggests that the model predicts substantial future underperformance compared to S&P 500.

**4. Recent News & Significant Events:**

*   Several recent news articles focus on UnitedHealth Group's significant share price drop in 2024 and potential recovery.
*   Analyst opinions seem mixed, with some suggesting the "floor is set" for recovery while others highlight negatives already priced in and a possible transition year in 2026.
*   David Tepper's sale of UNH stock is a notable event.
*   **Key Takeaway:** The news sentiment is cautious, acknowledging past struggles but hinting at potential future improvement.

**4-2. Analyst Opinions:**

*   **Consensus:** Buy
*   **Mean Rating:** 1.96 (Buy)
*   **Number of Opinions:** 25
*   **Target Price (Avg/High/Low):** 392.24 / 440.00 / 280.00

**Analysis:**

*   Despite the recent struggles, the analyst consensus remains positive, with a "Buy" rating.
*   The average target price of 392.24 suggests a potential upside from the current price of 328.14. However, the low target price of 280.00 indicates a wide range of opinions and some significant bearish sentiment.

**5. Recent Earnings Analysis:**

| Date       | EPS  | Revenue       |
| ---------- | ---- | ------------- |
| 2025-10-28 | 2.59 | 113.16 B$     |
| 2025-08-11 | 3.76 | 111.62 B$     |
| 2025-05-07 | 6.9  | 109.58 B$     |
| 2024-11-04 | 6.56 | 100.82 B$     |
| 2025-10-28 | 6.56 | 100.82 B$     |

**Analysis:**

*   Revenues have been consistently increasing over the past several quarters.
*   However, the most recent EPS (2.59) is significantly lower than the previous quarters, this is concerning.
* The repetition of "2025-10-28" may indicate duplicated data.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue     | Profit Margin |
| ------------ | ----------- | ------------- |
| 2025-09-30   | $113.16B    | 18.24%        |
| 2025-06-30   | $111.62B    | 17.93%        |
| 2025-03-31   | $109.58B    | 21.70%        |
| 2024-12-31   | $100.81B    | 21.14%        |
| 2024-09-30   | $100.82B    | 22.84%        |

**Capital and Profitability:**

| Quarter      | Equity      | ROE     |
| ------------ | ----------- | ------- |
| 2025-09-30   | $95.79B    | 2.45%   |
| 2025-06-30   | $94.72B    | 3.60%   |
| 2025-03-31   | $95.04B    | 6.62%   |
| 2024-12-31   | $92.66B    | 5.98%   |
| 2024-09-30   | $94.53B    | 6.41%   |

**Analysis:**

*   Revenue growth is evident.
*   Profit margins have decreased in the most recent quarters.
*   ROE has also significantly declined, suggesting decreased profitability relative to equity. This is particularly concerning.

**7. Comprehensive Analysis (Summary):**

*   **Negative Performance:** UNH has significantly underperformed the S&P 500.
*   **Downtrend:** The stock is in a short-term downtrend, trading below key moving averages.
*   **Mixed Signals:**  While the MRI suggests medium risk, the RSI is neutral.
*   **Concerning Forecast:** The expected return is highly negative (-216.9%).
*   **News and Sentiment:** Recent news highlights a share price drop, but analyst opinions are mixed, with a consensus "Buy" rating, indicating potential recovery.
*   **Decreasing Profitability:** EPS, profit margins, and ROE have declined, which is a cause for concern.
*   **Analyst Target Price:** While the consensus suggests an upside, there's a wide range of target prices, reflecting uncertainty.
*   **Revenue Growth:** Recent quarterly revenues have shown consistent growth.

**Overall Conclusion:**

Based on the provided data, UNH is currently facing significant challenges. While analyst consensus remains positive and revenue is growing, declining profitability, negative sentiment reflected in the news, and substantial underperformance compared to the S&P 500 warrant caution. The exceptionally negative expected return should be deeply investigated and understood before considering a long-term investment. The company's recent financial performance and market perception suggest careful consideration of risks and potential opportunities.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.